持股变动声明
Bioxcel Therapeutics(BTAI)06-12 07:05
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-070514 Size: 5 KB 网页链接
简介:Bioxcel Therapeutics, Inc.于2017年3月29日成为特拉华州公司,为BioXcel的全资附属公司。 BioXcel Therapeutics,Inc.或BTI是一家临床阶段的生物制药公司,专注于药物开发,利用新型人工智能或人工智能识别神经科学和免疫肿瘤学领域的下一波药物。他们的药物再创新方法利用现有批准的药物或经临床验证的产品候选药物以及大数据和专有机器学习算法来确定新的治疗指标。他们的两个最先进的临床开发项目是BXCL501,一种a2a肾上腺素能受体激动剂右美托咪定或Dex的舌下薄膜制剂,用于急性治疗由神经和精神疾病引起的激动,和BXCL701,一种用于治疗罕见形式的前列腺癌和胰腺癌。他们在2017年12月开始使用Dex在轻度可能AD中的IV制剂的1b期药代动力学/药效学或PK / PD安全性研究,并且他们计划在精神分裂症患者中使用Dex的IV制剂开始1b期药代动力学/药效学安全性研究,他们期望在2018年下半年报告这两项研究的数据。他们还打算在2018年开始两项计划的第二阶段概念证明或PoC开放标签临床试验。他们预计,到2018年底,计划在BXCL501计划的阶段2 PoC开放标签临床试验中提供的数据读数将可用。
今开:1.18 | 昨收:1.19 |
最高:1.21 | 最低:1.17 |
涨停价: | 跌停价: |
总市值:43911061 |
Bioxcel Therapeutics(BTAI)06-12 07:05
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-070514 Size: 5 KB 网页链接
Bioxcel Therapeutics(BTAI)06-12 18:05
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, items 5.03, 5.07, and 9.01 Accession Number: 0001104659-24-070503 Act: 34 Size: 234 KB 网页链接
Bioxcel Therapeutics(BTAI)06-18 01:25
$Bioxcel Therapeutics(BTAI)$ 144 Report of proposed sale of securities Accession Number: 0001971857-24-000411 Act: 33 Size: 5 KB 网页链接
Bioxcel Therapeutics(BTAI)06-18 01:55
$Bioxcel Therapeutics(BTAI)$ 144 Report of proposed sale of securities Accession Number: 0001971857-24-000412 Act: 33 Size: 5 KB 网页链接
Bioxcel Therapeutics(BTAI)06-25 19:15
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-074545 Act: 34 Size: 194 KB 网页链接
Bioxcel Therapeutics(BTAI)06-19 17:25
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-073002 Size: 12 KB 网页链接
Bioxcel Therapeutics(BTAI)06-19 17:25
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-073003 Size: 9 KB 网页链接
Bioxcel Therapeutics(BTAI)06-19 17:25
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-072999 Size: 15 KB 网页链接
Bioxcel Therapeutics(BTAI)06-07 08:35
$Bioxcel Therapeutics(BTAI)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-24-069194 Act: 34 Size: 72 KB 网页链接
Bioxcel Therapeutics(BTAI)06-12 07:05
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-070515 Size: 5 KB 网页链接
chuminhua2023-10-26 11:00
10/25,BioXcel Therapeutics $Bioxcel Therapeutics(BTAI)$ 宣布,独立第三方审计确认其实验性阿尔茨海默病治疗药物 BXCL501 的 III 期试验不存在数据完整性问题,周三该公司股价在盘前交易中上涨了 40%。
6 月,BioXcel 报告称,BXCL501 的 III 期 TRANQUILITY II 试验已达到其主要终点。BXC...查看全文
chuminhua2023-08-15 10:57
8/14,BioXcel Therapeutics $Bioxcel Therapeutics(BTAI)$ 仍因近期一项关键研究的数据完整性问题而困扰,宣布作为战略改革的一部分,将把员工人数从约 190 人减少到 80 人。 该公司股价周一下跌 45%,该公司表示,未来计划将重点放在“高潜力的激动人心的市场机会”上。
首席执行官 Vimal Me...查看全文
SeekingBiotech2023-08-14 21:34
BTAI reported its second quarter 2023 financials and announced plans to reduce nearly 60% of its workforce as part of a reprioritization of its business operation
$Bioxcel Therapeutics(BTAI)$
右美托咪定改良新药等。查看全文
不入流资讯2023-08-14 21:04
$Bioxcel Therapeutics(BTAI)$ BioXcel Therapeutics to cut workforce 58%, stock falls 30%查看全文
冷小二2023-08-11 10:24
$Bioxcel Therapeutics(BTAI)$ 还有救吗?目前似乎也没说一定是造假吧?According to Reuters, the company said one trial site's lead investigator was found to have fabricated emails related to the timing of a serious side effect with the company's vendor that was responsib...查看全文
美股律师郝俊波2023-07-08 12:02
$Bioxcel Therapeutics(BTAI)$ 【BioXcel Therapeutics(BTAI)最新证券集体诉讼】
BioXcel Therapeutics Inc(BTAI)因证券欺诈案已经于近日被投资者集体诉讼至法院。在目前的诉讼中投资者指控该公司及部分高管在本案诉讼期间进行虚假陈述,违反证券法令投资者受损。投资者向法院申请判令被告赔...查看全文
mx在隔壁2023-07-06 18:21
$Bioxcel Therapeutics(BTAI)$ 之前有什么利空跌这么多,好凶猛的期权查看全文
JZee2023-06-30 14:43
$Bioxcel Therapeutics(BTAI)$ 这治疗双相的药作假了多少不好说,这股民确实被整双相障碍了...查看全文
产业链观察2023-06-29 22:02
$Bioxcel Therapeutics(BTAI)$ 大跌,因为招募患者出了问题。查看全文
产业链观察2023-06-29 21:36
#药闻简讯# $Bioxcel Therapeutics(BTAI)$ 宣布BXCL501急性治疗阿尔茨海默病相关惊厥的TRANQUILITY II 3期试验取得积极的顶线结果。
试验达到了60微克剂量的主要终点,与安慰剂相比,BXCL501在2小时内的PEC评分从基线下降了39%,具有统计学意义(P=0.0112)。
实验达到了关键的次要终点,...查看全文
生物制药公司BioXcel Therapeutics(BTAI.US)盘前跌4.11%,报4.2美元。瑞穗将BioXcel Therapeutics的股票评级从“买入”下调至“中性”,并将其目标价从40美元下调至4美元,此前该公司在第二季度财报中宣布了重... 网页链接
格隆汇3月10日丨BioXcel Therapeutics(BTAI.US)现跌5.53%,报17.845美元,总市值5亿美元。BioXcel Therapeutics公布,2021年第四季度稀释后每股净亏损0.93美元,高于去年同期的每股亏损0.87美元,Capital IQ调查的分析师预计每股亏损1.14美元。 网页链接
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, item 1.01 Accession Number: 0001104659-24-080571 Act: 34 Size: 194 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-080022 Act: 34 Size: 243 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-074545 Act: 34 Size: 194 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-072999 Size: 15 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-072998 Size: 7 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-073003 Size: 9 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-073002 Size: 12 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-073000 Size: 9 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-073001 Size: 13 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-073004 Size: 13 KB 网页链接